Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Acta Oncologica (Stockholm, Sweden)
|
May 9, 2017
Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab
Abdul R Naqash, Geoffrey Stroud, Frances A Collichio, et al.
Blood Reviews
|
March 13, 2016
Epigenetics: A primer for clinicians
Benjamin E Paluch, Abdul R Naqash, Zachary Brumberger, et al.
Frontiers in Oncology
|
January 26, 2023
Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
Christine Son, Melissa Y Y Moey, Paul R Walker, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
December 7, 2017
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman Rg Stroud, Aparna Hegde, Cynthia Cherry, et al.
JACC. Cardiooncology
|
August 16, 2021
Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
Melissa Y Y Moey, Anna N Tomdio, Justin D McCallen, et al.
Nature Communications
|
November 13, 2025
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors
Xuefeng Wang, Tingyi Li, Islam Eljilany, et al.
Biorxiv : the Preprint Server for Biology
|
September 30, 2024
Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK
Shiela C Samson, Anthony Rojas, Rebecca G Zitnay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
David J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Acta Oncologica (Stockholm, Sweden)
|
May 9, 2017
Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab
Abdul R Naqash, Geoffrey Stroud, Frances A Collichio, et al.
Blood Reviews
|
March 13, 2016
Epigenetics: A primer for clinicians
Benjamin E Paluch, Abdul R Naqash, Zachary Brumberger, et al.
Frontiers in Oncology
|
January 26, 2023
Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
Christine Son, Melissa Y Y Moey, Paul R Walker, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|
December 7, 2017
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Chipman Rg Stroud, Aparna Hegde, Cynthia Cherry, et al.
JACC. Cardiooncology
|
August 16, 2021
Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
Melissa Y Y Moey, Anna N Tomdio, Justin D McCallen, et al.
Nature Communications
|
November 13, 2025
Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors
Xuefeng Wang, Tingyi Li, Islam Eljilany, et al.
Biorxiv : the Preprint Server for Biology
|
September 30, 2024
Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK
Shiela C Samson, Anthony Rojas, Rebecca G Zitnay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
Hamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.
The New England Journal of Medicine
|
September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Alice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 11, 2021
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice
David J Pinato, Thomas U Marron, Pallavi Shruti Mishra-Kalyani, et al.
Page
of 2